Please Wait.....
Report
Europe Cancer Therapy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)
Market Report I 2026-01-16 I 80 Pages I Mordor Intelligence
Europe Cancer Therapy Market Analysis
The Europe Cancer Therapy Market is expected to grow from USD 61.46 billion in 2025 to USD 64.72 billion in 2026 and is forecast to reach USD 83.69 billion by 2031 at 5.31% CAGR over 2026-2031.
This steady trajectory reflects regulatory harmonization by the European Medicines Agency (EMA), the expansion of precision medicine under the EU Beating Cancer Plan, and sustained R&D investment in leading economies, such as Germany and France. Intensifying competition centers on antibody-drug conjugates and radioligand therapies, while the uptake of biosimilars accelerates cost containment efforts across public health systems. Cross-border CAR-T manufacturing, digital biomarker deployment, and a surge in venture capital for radiopharmaceutical start-ups further widen the addressable demand. Cost pressures, divergent health-technology assessment (HTA) timelines, and gaps in nuclear-medicine infrastructure remain the principal obstacles to timely patient access.
Europe Cancer Therapy Market Trends and Insights
Precision-Oncology Drug Approvals Surge Post-EMA Reforms
EMA modernization has accelerated precision-oncology pathways, with 28 oncology opinions in 2024 versus historical single-digit figures. Conditional marketing authorizations shortened time to market for biomarker-driven agents such as lazertinib, which reached European patients within 12 months of pivotal data read-out and delivered 23.7 months median progression-free survival against 16.6 months for comparator therapy. Companies now prioritizing real-world-evidence generation gain a durable competitive edge, whereas developers reliant on legacy models face erosion in launch velocity. Harmonized procedures also reduce duplicative submissions, freeing capital for late-stage trials and life-cycle management.
Biosimilar Oncology Uptake Lowering Therapy Costs
Europe's biosimilar penetration triggered double-digit volume growth across molecules such as trastuzumab and rituximab, driving price erosion beyond 40% in leading markets. Physician confidence broadened adoption after real-world equivalence studies, enabling payers to reallocate savings to innovative therapies. Originators respond by emphasizing superior clinical differentiation and bundled service offerings. Multi-source competition intensifies procurement pressure, favoring manufacturers with high-throughput biologics capacity and robust pharmacovigilance data packages.
Divergent HTA Reimbursement Timelines Across EU-5
The W.A.I.T. (Waiting to Access Innovative Therapies) indicator survey shows an average 531-day lag between EMA approval and patient availability across the five largest markets, reflecting heterogeneous evidence and pricing requirements. While the 2025 Joint Clinical Assessment regulation aims to align methodologies, transitional frictions may widen gaps as national agencies recalibrate their value frameworks. Larger pharmaceutical firms leverage multi-disciplinary market-access teams to navigate parallel submissions, whereas smaller innovators risk launch postponements and revenue shortfalls.
Other drivers and restraints analyzed in the detailed report include:
Genomic Screening Roll-Outs in EU27 National Cancer PlansCross-Border CAR-T Manufacturing Hubs in Benelux InitiativeHospital Capacity Gap for Nuclear-Medicine-Based Therapies
For complete list of drivers and restraints, kindly check the Table Of Contents.
Segment Analysis
Chemotherapy retained a 41.92% share of the Europe cancer therapy market size in 2025, reflecting its entrenched role in combination regimens. Yet targeted therapy is forecast to post a 6.14% CAGR, propelled by HER2-low breast cancer approvals and next-generation EGFR inhibitors that extend progression-free intervals. A maturing immunotherapy backbone is increasingly paired with precision inhibitors, enabling deeper responses across various tumor types and elevating biomarker testing rates.
Increasing clinical trial density underscores a strategic emphasis on tumor-agnostic indications, with basket study designs compressing development cycles. Biosimilar erosion in traditional cytotoxics accelerates revenue migration toward precision platforms, prompting legacy manufacturers to replenish pipelines via licensing or bolt-on acquisitions. The shift also reorients hospital formularies toward outpatient administration, reinforcing payer preference for cost-effective, biomarker-guided protocols.
Breast cancer dominated the Europe cancer therapy market, accounting for a 25.12% share in 2025, driven by established screening programs and well-established treatment algorithms. However, lung cancer is slated for the fastest 6.77% CAGR through 2031 as first-line immunotherapy combinations and exon-20 insertion inhibitors unlock previously refractory segments.
Environmental policy tightening on smoking and air-quality metrics may gradually reduce incidence. Yet, the rapid adoption of molecular diagnostics broadens eligible patient pools for targeted regimens in the near term. Pharmaceutical companies thus prioritize portfolio depth across genomic subsets, balancing blockbuster volume in hormone-positive breast cancer with high-growth revenue in niche lung-cancer mutations.
The Europe Cancer Therapy Market Report is Segmented by Therapy Type (Chemotherapy, Targeted Therapy, and More), Cancer Type (Breast Cancer, Lung Cancer, and More), Drug Class (PD-1/PD-L1 Inhibitors, Tyrosine Kinase Inhibitors, and More), Mode of Administration (Intravenous, Subcutaneous, and More), and Country (Germany, United Kingdom, France, Italy, and More). The Market Forecasts are Provided in Terms of Value (USD).
List of Companies Covered in this Report:
Roche Novartis AstraZeneca Pfizer Bristol-Myers Squibb Merck Sanofi Johnson & Johnson ( Janssen Biotech ) GlaxoSmithKline Bayer Eli Lilly and Company Amgen Abbvie Boehringer Ingelheim Int'l GmbH Ipsen Daiichi Sankyo Takeda Pharmaceuticals Servier SAS Hikma Pharmaceuticals
Additional Benefits:
The market estimate (ME) sheet in Excel format
3 months of analyst support
1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Precision-Oncology Drug Approvals Surge Post-EMA Reforms
4.2.2 Biosimilar Oncology Uptake Lowering Therapy Costs
4.2.3 Genomic Screening Roll-Outs in EU27 National Cancer Plans
4.2.4 Cross-Border CAR-T Manufacturing Hubs in Benelux Initiative
4.2.5 VC Funding Boom or Radioligand Start-Ups
4.2.6 AI-Driven Trial-Matching Platforms Shorten Recruitment Time
4.3 Market Restraints
4.3.1 Divergent HTA Reimbursement Timelines Across EU-5
4.3.2 Hospital Capacity Gap for Nuclear-Medicine-Based Therapies
4.3.3 Oncology Workforce Shortages in CEE Nations
4.3.4 Rising Supply-Chain Risk for Critical API Imports
4.4 Value / Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter's Five Forces Analysis
4.7.1 Threat of New Entrants
4.7.2 Bargaining Power of Buyers
4.7.3 Bargaining Power of Suppliers
4.7.4 Threat of Substitutes
4.7.5 Competitive Rivalry
5 Market Size & Growth Forecasts
5.1 By Therapy Type
5.1.1 Chemotherapy
5.1.2 Targeted Therapy
5.1.3 Immunotherapy
5.1.4 Hormonal Therapy
5.1.5 Other Therapy Type
5.2 By Cancer Type
5.2.1 Breast Cancer
5.2.2 Lung Cancer
5.2.3 Colorectal Cancer
5.2.4 Prostate Cancer
5.2.5 Hematologic Cancers
5.2.6 Other Cancer Types
5.3 By Drug Class
5.3.1 PD-1/PD-L1 Inhibitors
5.3.2 Tyrosine Kinase Inhibitors
5.3.3 CDK4/6 Inhibitors
5.3.4 Hormone Antagonists
5.3.5 Antibody-Drug Conjugates
5.3.6 Other Drug Classes
5.4 By Mode of Administration
5.4.1 Intravenous
5.4.2 Subcutaneous
5.4.3 Oral
5.4.4 Other Mode of Administration
5.5 Country
5.5.1 Germany
5.5.2 United Kingdom
5.5.3 France
5.5.4 Italy
5.5.5 Spain
5.5.6 Rest of Europe
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global level Overview, Market Level Overview, Core Segments, Financials as Available, Strategic Information, Market Rank/Share for Key Companies, Products & Services, and Recent Developments)
6.3.1 F. Hoffmann-La Roche AG
6.3.2 Novartis AG
6.3.3 AstraZeneca PLC
6.3.4 Pfizer Inc.
6.3.5 Bristol-Myers Squibb Company
6.3.6 Merck & Co., Inc.
6.3.7 Sanofi S.A.
6.3.8 Johnson & Johnson ( Janssen Biotech )
6.3.9 GlaxoSmithKline PLC
6.3.10 Bayer AG
6.3.11 Eli Lilly and Company
6.3.12 Amgen Inc.
6.3.13 AbbVie Inc.
6.3.14 Boehringer Ingelheim Int'l GmbH
6.3.15 Ipsen S.A.
6.3.16 Daiichi Sankyo Company Ltd.
6.3.17 Takeda Pharmaceutical Company Ltd.
6.3.18 Servier SAS
6.3.19 Hikma Pharmaceuticals PLC
7 Market Opportunities & Future Outlook
7.1 White-space & Unmet-Need Assessment
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security